Active surveillance of low-risk papillary thyroid microcarcinoma

Independent study shows favorable long term prognosis for CP-GEP Low Risk melanoma patients

Retrieved on: 
Friday, March 17, 2023
Risk, High Risk, University, CP-GEP, European Journal of Cancer Prevention, Cancer, Research, Gene expression, Gene expression profiling, RFS, Medicare, Patient, Melanoma, SAN, Active surveillance of low-risk papillary thyroid microcarcinoma, Diagnosis, Lymph node, European Journal, Inflammation, Pharmaceutical industry, Medical imaging

The University of Tuebingen (Germany) study analyzed 543 patients diagnosed with stage I/II primary cutaneous melanoma between 2000 and 2017.

Key Points: 
  • The University of Tuebingen (Germany) study analyzed 543 patients diagnosed with stage I/II primary cutaneous melanoma between 2000 and 2017.
  • It found that when combined with clinicopathologic factors, the CP-GEP model can be used to stratify these patients into high risk and low risk cohorts for disease recurrence.
  • Specifically, the patients determined to have Low Risk have an almost five times favorable 5-year recurrence free survival (RFS) over the CP-GEP High Risk patients in stage I/II melanoma, with 93% of low-risk patients are recurrence-free 5 years after diagnosis [2].
  • "The Merlin test can drive a profound economic benefit by significantly reducing the number of SLNB procedures performed on Low Risk melanoma patients.

Independent study shows favorable long term prognosis for CP-GEP Low Risk melanoma patients

Retrieved on: 
Friday, March 17, 2023
Risk, High Risk, University, CP-GEP, European Journal of Cancer Prevention, Cancer, Research, Gene expression, Gene expression profiling, RFS, Medicare, Patient, Melanoma, SAN, Active surveillance of low-risk papillary thyroid microcarcinoma, Diagnosis, Lymph node, European Journal, Inflammation, Pharmaceutical industry, Medical imaging

The University of Tuebingen (Germany) study analyzed 543 patients diagnosed with stage I/II primary cutaneous melanoma between 2000 and 2017.

Key Points: 
  • The University of Tuebingen (Germany) study analyzed 543 patients diagnosed with stage I/II primary cutaneous melanoma between 2000 and 2017.
  • It found that when combined with clinicopathologic factors, the CP-GEP model can be used to stratify these patients into high risk and low risk cohorts for disease recurrence.
  • Specifically, the patients determined to have Low Risk have an almost five times favorable 5-year recurrence free survival (RFS) over the CP-GEP High Risk patients in stage I/II melanoma, with 93% of low-risk patients are recurrence-free 5 years after diagnosis [2].
  • "The Merlin test can drive a profound economic benefit by significantly reducing the number of SLNB procedures performed on Low Risk melanoma patients.

SM recognized as top rated sustainability company in both industry and Asia Pacific

Retrieved on: 
Friday, March 10, 2023
Social, Biophysical environment, Research, Social Security Government Pension Offset, Top, Growth, Diversification, Diversified financial, SM Investments, ESG, SM, Risk management, Investment, Risk, Active surveillance of low-risk papillary thyroid microcarcinoma, Cryptocurrency

PASAY CITY, Philippines, March 10, 2023 /PRNewswire/ -- SM Investments Corporation (SM Investments) was recognized as among the Top Rated companies in its industry (Diversified Financial) globally, and also among Top Rated companies in the Asia Pacific, in a 2023 Top-Rated ESG Companies list by international ratings firm Morningstar Sustainalytics.

Key Points: 
  • PASAY CITY, Philippines, March 10, 2023 /PRNewswire/ -- SM Investments Corporation (SM Investments) was recognized as among the Top Rated companies in its industry (Diversified Financial) globally, and also among Top Rated companies in the Asia Pacific, in a 2023 Top-Rated ESG Companies list by international ratings firm Morningstar Sustainalytics.
  • The rating means SM Investments belongs to the strongly performing 6.7 percent of companies with the lowest ESG risk score within its defined peer group.
  • "We are honoured to be cited by Morningstar Sustainalytics which reflects our commitment and initiatives towards sustainability, particularly good governance and risk management.
  • The firm also works with hundreds of companies and their financial intermediaries to help them consider sustainability in policies, practices, and capital projects.

SM recognized as top rated sustainability company in both industry and Asia Pacific

Retrieved on: 
Friday, March 10, 2023
Social, Biophysical environment, Research, Social Security Government Pension Offset, Top, Growth, Diversification, Diversified financial, SM Investments, ESG, SM, Risk management, Investment, Risk, Active surveillance of low-risk papillary thyroid microcarcinoma, Cryptocurrency

PASAY CITY, Philippines, March 9, 2023 /PRNewswire/ -- SM Investments Corporation (SM Investments) was recognized as among the Top Rated companies in its industry (Diversified Financial) globally, and also among Top Rated companies in the Asia Pacific, in a 2023 Top-Rated ESG Companies list by international ratings firm Morningstar Sustainalytics.

Key Points: 
  • PASAY CITY, Philippines, March 9, 2023 /PRNewswire/ -- SM Investments Corporation (SM Investments) was recognized as among the Top Rated companies in its industry (Diversified Financial) globally, and also among Top Rated companies in the Asia Pacific, in a 2023 Top-Rated ESG Companies list by international ratings firm Morningstar Sustainalytics.
  • The rating means SM Investments belongs to the strongly performing 6.7 percent of companies with the lowest ESG risk score within its defined peer group.
  • "We are honoured to be cited by Morningstar Sustainalytics which reflects our commitment and initiatives towards sustainability, particularly good governance and risk management.
  • The firm also works with hundreds of companies and their financial intermediaries to help them consider sustainability in policies, practices, and capital projects.

PreludeDx™ Presents New Data at the 40th Annual Miami Breast Cancer Conference Identifying Which Patients with DCIS May Be Undertreated Based on Clinicopathologic Factors Alone

Retrieved on: 
Thursday, March 2, 2023
Patient, CP, Additive effect, Active surveillance of low-risk papillary thyroid microcarcinoma, Washington University School of Medicine, Woman, HT, DCIS, MBCC, FACS, Therapy, Fontainebleau Miami Beach, Conference, Alvin J. Siteman Cancer Center, Breast, Clinical research, MSKCC, Cleveland Clinic, Ductal carcinoma, Memorial Sloan Kettering Cancer Center, RT, Medicine, Poster, IBR, Comparative oncology, Nomogram, BCS, Medical imaging, Nursing, Pharmaceutical industry, Radiation therapy, MD

LAGUNA HILLS, Calif., March 2, 2023 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will be presenting data comparing risk stratification and radiation benefit (RT) for patients with ductal carcinoma in situ (DCIS) using DCISionRT™ with a clinicopathologic (CP) model similar to the Memorial Sloan Kettering Cancer Center (MSKCC) DCIS nomogram at the 40th Annual Miami Breast Cancer Conference (MBCC), being held on March 2 – 5, 2023 at the Fontainebleau Miami Beach.

Key Points: 
  • The study included 926 DCIS patients from four cohorts who were treated with breast conserving surgery (BCS) or BCS + radiation therapy (RT).
  • The study compared MSKCC DCIS nomogram-like model with the DCISionRT 7-gene biosignature.
  • "DCISionRT provides us the clinical evidence to identify which DCIS patients, despite having low-risk clinicopathologic features, can actually benefit from RT and which patients may safely omit RT."
  • The registry includes females 26 and older who are diagnosed with DCIS and are candidates for BCS and eligible for RT.